A Randomized Phase III, Factorial Design, of Cabazitaxel and Pelvic Radiotherapy in Patients With Localized Prostate Cancer and High-risk Features of Relapse
Phase of Trial: Phase III
Latest Information Update: 13 Dec 2018
Price : $35 *
At a glance
- Drugs Cabazitaxel (Primary) ; Antiandrogens; LHRH receptor agonists; LHRH receptor antagonists
- Indications Prostate cancer
- Focus Registrational; Therapeutic Use
- Acronyms PEACE2
- Sponsors UNICANCER
- 31 Aug 2018 Biomarkers information updated
- 06 May 2018 Planned End Date changed from 1 Sep 2026 to 1 Dec 2032.
- 06 May 2018 Planned primary completion date changed from 1 Sep 2019 to 1 Dec 2025.